Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)
Viatris (VTRS) posted quarterly Depreciation & Amortization (CF) of $676.1 million for Q1 2026, up 1.72% year-over-year from $664.7 million in Q1 2025, and down 11.83% quarter-over-quarter from $766.8 million in Q4 2025.
Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Viatris' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $676.1 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 1.72% year-over-year to $676.1 million; the TTM figure through Mar 2026 stood at $2.8 billion (down 2.0% YoY), while the FY2025 annual figure was $2.8 billion, down 3.28% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $676.1 million, down from $766.8 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $869.8 million in Q4 2022, with the low at $644.4 million in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $691.0 million (2024), against an average of $713.9 million.
- Peak annual rise in Depreciation & Amortization (CF) reached 16.0% in 2022, while the deepest fall reached 48.26% in 2022.
- Viatris' Depreciation & Amortization (CF) stood at $869.8 million in 2022, then decreased by 25.91% to $644.4 million in 2023, then rose by 15.8% to $746.2 million in 2024, then rose by 2.76% to $766.8 million in 2025, then fell by 11.83% to $676.1 million in 2026.
- Business Quant data shows VTRS's Depreciation & Amortization (CF) at $676.1 million in Q1 2026, $766.8 million in Q4 2025, and $688.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 672.30 Mn |
| Jun 30, 2026 | 672.30 Mn |
| Mar 31, 2026 | 676.10 Mn |
| Mar 31, 2026 | 676.10 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Mar 31, 2024 | 691.00 Mn |